Effector and suppressor T cells in celiac disease

Area of Science:

• Immunology
• Gastroenterology

Background:

• Celiac disease (CD) is an immune-mediated condition triggered by gliadin peptides.
• Effector CD4+ T cells, particularly Th17 cells, are implicated in CD pathogenesis through pro-inflammatory cytokine release.
• The immune response in CD involves a complex interplay of effector and regulatory T cell subsets.

Discussion:

• Th17 cells, characterized by high IL-17A expression, contribute to tissue injury in celiac disease.
• The balance between pro-inflammatory Th17 cells and regulatory T cells (Tregs) is critical in CD.
• Regulatory T cell subsets, including type 1 regulatory T cells and CD25(+)CD4(+) Tregs expressing Foxp3, are being investigated for their suppressive functions in CD.

Key Insights:

• Gliadin peptides activate pathogenic effector T cells in celiac disease.
• Th17 cells play a significant role in the inflammatory processes and tissue damage observed in CD.
• Regulatory T cells, such as Foxp3+ Tregs, show potential in modulating the immune response and influencing disease progression in celiac disease.

Outlook:

• Further research into the specific roles of Th17 and regulatory T cells could reveal new therapeutic targets for celiac disease.
• Understanding the balance between effector and regulatory T cells is crucial for managing CD.
• Investigating Foxp3+ regulatory T cells may lead to strategies for immune tolerance induction in celiac disease.